Salvage chemotherapy in Hodgkin's disease. Results in patients relapsing more than twelve months after first complete remission

Ann Oncol. 1990;1(2):123-7. doi: 10.1093/oxfordjournals.annonc.a057689.

Abstract

Forty-nine patients with Hodgkin's disease who relapsed after a first complete remission of more than 12 months following primary chemotherapy were treated with salvage therapy regimens. A total of 41 patients (84%) achieved complete remission. In particular, complete response was documented in 17 of 19 patients re-treated with the same initial drug combination. The five-year freedom from progression, relapse-free and overall survivals were 51%, 57% and 65%, respectively. In our experience, consolidation radiotherapy following drug-induced remission failed to improve the five-year relapse-free survival. Present findings indicate that about half of patients relapsing after a disease-free interval exceeding 12 months can remain alive and disease-free 5 years after starting salvage chemotherapy.

MeSH terms

  • Adult
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Bleomycin / administration & dosage
  • Dacarbazine / administration & dosage
  • Doxorubicin / administration & dosage
  • Etoposide / administration & dosage
  • Female
  • Hodgkin Disease / drug therapy*
  • Hodgkin Disease / mortality
  • Hodgkin Disease / pathology
  • Humans
  • Lomustine / administration & dosage
  • Male
  • Mechlorethamine / administration & dosage
  • Middle Aged
  • Prednimustine / administration & dosage
  • Prednisone / administration & dosage
  • Procarbazine / administration & dosage
  • Recurrence
  • Vinblastine
  • Vincristine / administration & dosage

Substances

  • Bleomycin
  • Procarbazine
  • Mechlorethamine
  • Vincristine
  • Vinblastine
  • Etoposide
  • Lomustine
  • Dacarbazine
  • Doxorubicin
  • Prednimustine
  • Prednisone

Supplementary concepts

  • ABVD protocol
  • CEP protocol
  • MOPP protocol